Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Vivesto AB ( (SE:VIVE) ) is now available.
Vivesto AB has announced the appointment of its Nomination Committee for the 2026 Annual General Meeting, following the ownership structure as of September 30, 2025. The committee consists of Per Arwidsson, Christer Hasslebäck, and Peter Zonabend, with Arwidsson as Chairman. The AGM is scheduled for May 7, 2026, in Stockholm, and shareholders are invited to submit proposals by January 31, 2026.
More about Vivesto AB
Vivesto AB is a Swedish development company focused on creating new treatment options for hard-to-treat cancers, addressing significant medical needs and market potential. Their project portfolio includes Cantrixil for blood cancer and the veterinary oncology program Paccal Vet, which is under evaluation in clinical trials for dogs and cats with specific cancers.
Average Trading Volume: 524,772
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK123.7M
Learn more about VIVE stock on TipRanks’ Stock Analysis page.